Nicotinic α4β2 receptor binding in dementia with Lewy bodies using 123I-5IA-85380 SPECT demonstrates a link between occipital changes and visual hallucinations

NeuroImage

Volumn 40, Issue 3, 2008, Pages 1056-1063

  O'Brien, John T ^a   Colloby, Sean J ^a   Pakrasi, Sanjeet ^a   Perry, Elaine K ^a   Pimlott, Sally L ^b   Wyper, David J ^c   McKeith, Ian G ^a   Williams, E David ^d  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b WESTERN INFIRMARY   (United Kingdom)

^c SOUTHERN GENERAL HOSPITAL   (United Kingdom)

^d SUNDERLAND ROYAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 (2 AZETIDINYLMETHOXY)PYRIDINE; 5 IODO 3 (2 AZETIDINYLMETHOXY)PYRIDINE I 123; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; IODINE 123; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ALPHA4BETA2; UNCLASSIFIED DRUG; 5 IODO 3 (2 AZETIDINYLMETHOXY)PYRIDINE; 5-IODO-3-(2-AZETIDINYLMETHOXY)PYRIDINE; ALKANONE; AZETIDINE DERIVATIVE; DIAGNOSTIC AGENT; EXAMETAZIME; PYRIDINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

AGED; ARTICLE; BRAIN MAPPING; BRAIN PERFUSION; CHOLINERGIC SYSTEM; CINGULATE GYRUS; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIFFUSE LEWY BODY DISEASE; DRUG UPTAKE; FEMALE; FRONTAL LOBE; HUMAN; IMAGE ANALYSIS; IMAGE DISPLAY; IMAGE ENHANCEMENT; IMAGE PROCESSING; MALE; NEUROIMAGING; OCCIPITAL LOBE; PRIORITY JOURNAL; RECEPTOR BINDING; SCINTILLATION CAMERA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRIATE CORTEX; TEMPORAL LOBE; VISUAL HALLUCINATION; HALLUCINATION; METABOLISM; NEUROPSYCHOLOGICAL TEST; PATHOPHYSIOLOGY; SCINTISCANNING;

AGED; AZETIDINES; BUTANONES; FEMALE; HALLUCINATIONS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LEWY BODY DISEASE; MALE; NEUROPSYCHOLOGICAL TESTS; OCCIPITAL LOBE; PYRIDINES; RADIOPHARMACEUTICALS; RECEPTORS, NICOTINIC; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 40849120308     PISSN: 10538119     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2008.01.010     Document Type: Article

References (44)

1. Acton P.D., and Friston K.J. Statistical parametric mapping in functional neuroimaging: beyond PET and fMRI activation studies. Eur. J. Nucl. Med. 25 (1998) 663-667
2. Brett, M., 1999. The MNI brain and the Talairach Atlas. MRC Cognition and Brain Sciences Unit. http://www.mrc-cbu.cam.ac.uk/Imaging/contents.html.
3. Chatfield C., and Collins A.J. Introduction to Multivariate Analysis (1980) 189-210
4. Colloby S.J., Fenwick J.D., Williams E.D., Paling S.M., Lobotesis K., Ballard C., McKeith I., and O'Brien J.T. A comparison of (99m)Tc-HMPAO SPET changes in dementia with Lewy bodies and Alzheimer's disease using statistical parametric mapping. Eur. J. Nucl Med. Mol. Imaging 29 (2002) 615-622
5. Colloby S.J., Pakrasi S., Firbank M.J., Perry E.K., Piggott M.A., Owens J., Wyper D.J., McKeith I.G., Burn D.J., Williams E.D., and O'Brien J.T. In vivo SPECT imaging of muscarinic acetylcholine receptors using (R,R) 123I-QNB in dementia with Lewy bodies and Parkinson's disease dementia. NeuroImage 33 (2006) 423-429
6. Court J., Spurden D., Lloyd S., McKeith I., Ballard C., Cairns N., Kerwin R., Perry R., and Perry E. Neuronal nicotinic receptors in dementia with Lewy bodies and schizophrenia: alpha-bungarotoxin and nicotine binding in the thalamus. J. Neurochem. 73 (1999) 1590-1597
7. Court J.A., Ballard C.G., Piggott M.A., Johnson M., O'Brien J.T., Holmes C., Cairns N., Lantos P., Perry R.H., Jaros E., and Perry E.K. Visual hallucinations are associated with lower alpha bungarotoxin binding in dementia with Lewy bodies. Pharmacol. Biochem. Behav. 70 (2001) 571-579
8. Cummings J.L., Mega M., Gray K., Rosenberg-Thompson S., Carusi D.A., and Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44 (1994) 2308-2314
9. Fahn S., Elton R.L., Marsden C.D., and Goldstein M. Unified Parkinson's disease rating scale. Recent developments in Parkinson's disease. Macmillan (1987) 153-163
10. Folstein M.F., Folstein S.E., and McHugh P.R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12 (1975) 189-198
11. Frackowiak R.S., Friston K.J., Frith C.D., Dolan R.J., and Mazziotta J.C. Human Brain Function, First ed (1997), Academic Press, London
12. Friston K.J., Worsley K.J., Frackowiak R.S.J., Mazziotta J.C., and Evans A.C. Assessing the significance of focal activations using their spatial extent. Hum. Brain Map 1 (1994) 214-220
13. Fujita M., Ichise M., Zoghbi S.S., Liow J.S., Ghose S., Vines D.C., Sangare J., Lu J.Q., Cropley V.L., Iida H., Kim K.M., Cohen R.M., Bara-Jimenez W., Ravina B., and Innis R.B. Widespread decrease of nicotinic acetylcholine receptors in Parkinson's disease. Ann. Neurol. 59 (2006) 174-177
14. Fujita M., Seibyl J.P., Vaupel D.B., Tamagnan G., Early M., Zoghbi S.S., Baldwin R.M., Horti A.G., Koren A.O., Mukhin A.G., Khan S., Bozkurt A., Kimes A.S., London E.D., and Innis R.B. Whole-body biodistribution, radiation absorbed dose, and brain SPET imaging with I-123 5-I-A-85380 in healthy human subjects. Eur. J. Nucl. Med. Mol. Imaging 29 (2002) 183-190
15. Gotti C., Moretti M., Bohr I., Ziabreva I., Vailati S., Longhi R., Riganti L., Gaimarri A., McKeith I.G., Perry R.H., Aarsland D., Larsen J.P., Sher E., Beattie R., Clementi F., and Court J.A. Selective nicotinic acetylcholine receptor subunit deficits identified in Alzheimer's disease, Parkinson's disease and dementia with Lewy bodies by immunoprecipitation. Neurobiol. Dis. 23 (2006) 481-489
16. Imamura T., Ishii K., Hirono N., Hashimoto M., Tanimukai S., Kazuai H., Hanihara T., Sasaki M., and Mori E. Visual hallucinations and regional cerebral metabolism in dementia with Lewy bodies (DLB). Neuroreport 10 (1999) 1903-1907
17. Jones S., Sudweeks S., and Yakel J.L. Nicotinic receptors in the brain: correlating physiology with function. Trends Neurosci. 22 (1999) 555-561
18. Kadir A., Almkvist O., Wall A., Langstrom B., and Nordberg A. PET imaging of cortical (11)C-nicotine binding correlates with the cognitive function of attention in Alzheimer's disease. Psychopharmacology (Berl) (2006)
19. Le Novere N., and Changeux J.P. Molecular evolution of the nicotinic acetylcholine receptor: an example of multigene family in excitable cells. J. Mol. Evol. 40 (1995) 155-172
20. Lobotesis K., Fenwick J.D., Phipps A., Ryman A., Swann A., Ballard C., McKeith I.G., and O'Brien J.T. Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Neurology 56 (2001) 643-649
21. McKeith I.G., Galasko D., Kosaka K., Perry E.K., Dickson D.W., Hansen L.A., Salmon D.P., Lowe J., Mirra S.S., Byrne E.J., Lennox G., Quinn N.P., Edwardson J.A., Ince P.G., Bergeron C., Burns A., Miller B.L., Lovestone S., Collerton D., Jansen E.N., Ballard C., de Vos R.A., Wilcock G.K., Jellinger K.A., and Perry R.H. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47 (1996) 1113-1124
22. McKeith I.G., Ballard C.G., Perry R.H., Ince P.G., O'Brien J.T., Neill D., Lowery K., Jaros E., Barber R., Thompson P., Swann A., Fairbairn A.F., and Perry E.K. Prospective validation of Consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology 54 (2000) 1050-1058
23. Minoshima S., Foster N.L., Sima A.A.F., Frey K.A., Albin R.L., and Kuhl D.E. Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann. Neurol. 50 (2001) 358-365
24. Mori T., Ikeda M., Fukuhara R., Nestor P.J., and Tanabe H. Correlation of visual hallucinations with occipital rCBF changes by donepezil in DLB. Neurology 66 (2006) 935-937
25. Musachio J.L., Villemagne V.L., Scheffel U.A., Dannals R.F., Dogan A.S., Yokoi F., and Wong D.F. Synthesis of an I-123 analog of A-85380 and preliminary SPECT imaging of nicotinic receptors in baboon. Nucl. Med. Biol. 26 (1999) 201-207
26. Nordberg A., Amberla K., Shigeta M., Lundqvist H., Viitanen M., Hellstrom-Lindahl E., Johansson M., Andersson J., Hartvig P., Lilja A., Langstrom B., and Winblad B. Long-term tacrine treatment in three mild Alzheimer patients: effects on nicotinic receptors, cerebral blood flow, glucose metabolism, EEG, and cognitive abilities. Alzheimer Dis. Assoc. Disord. 12 (1998) 228-237
27. Nordberg A., Lundqvist H., Hartvig P., Lilja A., and Langstrom B. Kinetic analysis of regional (S)(-)11C-nicotine binding in normal and Alzheimer brains-in vivo assessment using positron emission tomography. Alzheimer. Dis. Assoc. Disord. 9 (1995) 21-27
28. O'Brien J.T., Colloby S., Fenwick J., Williams E.D., Firbank M., Burn D., Aarsland D., and McKeith I.G. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol 61 (2004) 919-925
29. O'Brien, J.T., Colloby S.J., Pakrasi S., Perry E.K., Pimlott S.L., Wyper D.J., McKeith I.G., and Williams E.D. Alpha 4 beta 2 nicotinic receptor status in Alzheimer's disease using 123I-5IA-85380 SPECT. J. Neurol. Neurosurg. Psychiatry. (2006)
30. Pasquier J., Michel B.F., Brenot-Rossi I., Hassan-Sebbag N., Sauvan R., and Gastaut J.L. Value of (99m)Tc-ECD SPET for the diagnosis of dementia with Lewy bodies. Eur. J. Nucl. Med. Mol. Imaging 29 (2002) 1342-1348
31. Perry E.K., Irving D., Kerwin J.M., McKeith I.G., Thompson P., Collerton D., Fairbairn A.F., Ince P.G., Morris C.M., Cheng A.V., and Perry R.H. Cholinergic transmitter and neurotrophic activities in Lewy body dementia-similarity to Parkinson and distinction from Alzheimer-disease. Alzheimer. Dis. Assoc. Disord. 7 (1993) 69-79
32. Perry E.K., Morris C.M., Court J.A., Cheng A., Fairbairn A.F., McKeith I.G., Irving D., Brown A., and Perry R.H. Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: possible index of early neuropathology. Neuroscience 64 (1995) 385-395
33. Pimlott S.L., Piggott M., Owens J., Greally E., Court J.A., Jaros E., Perry R.H., Perry E.K., and Wyper D. Nicotinic acetylcholine receptor distribution in Alzheimer's disease, dementia with Lewy bodies, Parkinson's disease, and vascular dementia: in vitro binding study using 5-[(125)i]-a-85380. Neuropsychopharmacology 29 (2004) 108-116
34. Prusky G.T., Shaw C., and Cynader M.S. The distribution and ontogenesis of [3H]nicotine binding sites in cat visual cortex. Brain Res. 467 (1988) 161-176
35. Ray M., Bohr I., McIntosh J.M., Ballard C., McKeith I., Chalon S., Guilloteau D., Perry R., Perry E., Court J.A., and Piggott M. Involvement of alpha6/alpha3 neuronal nicotinic acetylcholine receptors in neuropsychiatric features of dementia with Lewy bodies: [(125)I]-alpha-conotoxin MII binding in the thalamus and striatum. Neurosci. Lett 372 (2004) 220-225
36. Reid R.T., Sabbagh M.N., Corey-Bloom J., Tiraboschi P., and Thal L.J. Nicotinic receptor losses in dementia with Lewy bodies: comparisons with Alzheimer's disease. Neurobiol Aging 21 (2000) 741-746
37. Rodriguez-Puertas R., Pascual J., Vilaro T., and Pazos A. Autoradiographic distribution of M1, M2, M3, and M4 muscarinic receptor subtypes in Alzheimer's disease. Synapse 26 (1997) 341-350
38. Rossner S., Kues W., Witzemann V., and Schliebs R. Laminar expression of m1-, m3- and m4-muscarinic cholinergic receptor genes in the developing rat visual cortex using in situ hybridization histochemistry. Effect of monocular visual deprivation. Int. J. Dev. Neurosci. 11 (1993) 369-378
39. Roth M., Tym E., Mountjoy C.Q., Huppert F.A., Hendrie H., Verma S., and Goddard R. CAMDEX A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia. Br. J. Psychiatry 149 (1986) 698-709
40. Tiraboschi P., Hansen L.A., Alford M., Sabbagh M.N., Schoos B., Masliah E., Thal L.J., and Corey-Bloom J. Cholinergic dysfunction in diseases with Lewy bodies. Neurology 54 (2000) 407-411
41. Volkow N.D., Ding Y.S., Fowler J.S., and Gatley S.J. Imaging brain cholinergic activity with positron emission tomography: its role in the evaluation of cholinergic treatments in Alzheimer's dementia. Biol. Psychiatry 49 (2001) 211-220
42. Walker M.P., Ayre G.A., Cummings J.L., Wesnes K., McKeith I.G., O'Brien J.T., and Ballard C.G. The Clinician Assessment of Fluctuation and the One Day Fluctuation Assessment Scale. Two methods to assess fluctuating confusion in dementia. Br. J. Psychiatry 177 (2000) 252-256
43. Walker Z., Costa D.C., Walker R.W., Lee L., Livingston G., Jaros E., Perry R., McKeith I., and Katona C.L. Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: a comparison. Neurology 62 (2004) 1568-1572
44. Yamamoto R., Iseki E., Murayama N., Minegishi M., Marui W., Togo T., Katsuse O., Kato M., Iwatsubo T., Kosaka K., and Arai H. Investigation of Lewy pathology in the visual pathway of brains of dementia with Lewy bodies. J. Neurol. Sci. 246 (2006) 95-101